Close
Sherri Cervantez, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sherri Cervantez, MD
Dr. Sherri Cervantez is an assistant professor at The University of Texas Health Science Center San Antonio with a joint appointment to the Division of Hematology and Oncology and the Division of Geriatrics, Gerontology, and Palliative Medicine. She earned her bachelor's degree in neuroscience and behavioral biology from Emory University. She received her medical doctorate from Virginia Commonwealth University and completed her residency in internal medicine at West Virginia University. She completed a Hospice and Palliative Medicine fellowship at Virginia Commonwealth University before completing her Hematology and Oncology fellowship at UT Health San Antonio. She joined the Mays Cancer Center in 2017 as Director of Palliative Oncology. Her clinical interests include lung cancers, head and neck cancers and palliative oncology. Her research focuses on early integration of palliative care and best practices for interdisciplinary teams through quality improvement practices.
Explore the compassionate and holistic world of palliative care with Dr. Sherri Cervantez on Lung Cancer Foundation of America's Hope With Answers: Living With Lung Cancer.
Gender
- Female
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Assistant Professor, University of Texas Health Science Center San Antonio
- Director of Palliative Oncology, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Hospice & Palliative Medicine
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: Medicine, Virginia Commonwealth University, Richmond, Virginia
- Residency: Internal Medicine, West Virginia University Hospital, Morgantown, West Virginia
- Fellowship: Hospice ad Palliative Medicine, Virginia Commonwealth University, Richmond, VA
- Fellowship: Hematology and Oncology, University of Texas Health Science Center San Antonio, San Antonio, Texas
- Undergraduate: Neuroscience and Behavioral Biology, Emory University, Atlanta, Georgia
- Locations & Contact
-
Research & Publications
Research & Publications
Comprehensive care for patients with hepatocellular carcinoma: insights from the 2022 San Antonio Liver Cancer Symposium
Arora SP, Cervantez SR.
Pilot study evaluating feasibility and utility of pharmacist-driven oral antineoplastic agent monitoring program
Allen SM, Cervantez SR, Frei BL, Koeller JM.
Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report
Tripathy S, Alvarez N, Jaiswal S, Williams R, Al-Khadimi M, Hackman S, Phillips W, Kaur S, Cervantez S, Kelly W, Taverna J.
View All Publications - Sherri Cervantez, MD
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
S2302, PRAGMATICA – LUNG - A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionabl
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
Type of Cancer
Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nabpaclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
Metabolic kinetic phenotyping to predict cachexia and health outcomes in response to chemoradiation in patients with Head & Neck Cancer
Fifteen patients with advanced H&N cancer who will receive chemoradiation therapy as first line treatment will be studied (as weight loss is expected). The cancer patients will be recruited at the UT Health Mays Cancer Center (MCC) in San Antonio with testing to be performed at the Barshop Institute. The cancer group will be compared to 15 control subjects, recruited at CTRAL (Center for…